Skip to main content
OpenTrials
Completed

NCT Number: NCT00241943

A Video-Based HCV Curriculum for Active Injection Drug Users

The investigators hypothesize that a well-designed hepatitis C (HCV) video education curriculum for active drug injectors will lead to measurable improvements in HCV testing rates, HAV and HBV vaccination rates, as well as knowledge and attitudes about this condition. The investigators will use a short 10 minute video designed for active drug users to and assess its impact vs. a usual-care counseling intervention. The investigators will measure and compare its impact at baseline, 4 weeks after video viewing, and 12 weeks after intervention.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hepatitis C Blood-Borne Infections Chemically-Induced Disorders Communicable Diseases Digestive System Diseases Flaviviridae Infections Hepatitis Hepatitis, Viral, Human Infections Liver Diseases Mental Disorders Narcotic-Related Disorders Opiate Dependence Opioid-Related Disorders RNA Virus Infections Substance-Related Disorders Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

HEPPAC

Oakland, California, 94601, United States

About this study

Active drug injectors are at high risk for contracting and transmitting HCV. Very few culturally-specific tools have been developed to improve outcomes in this population. We hypothesize that measurable improvements in HCV testing rates, hepatitis A and B vaccination rates, and knowledge, attitudes, and motivations toward behavior change may be elicited by such a curriculum.

In this study, we will investigate the impact of a short HCV education video on active drug injectors at a syringe exchange program. Subjects will be enrolled in one of two cohorts: a usual-care cohort, which will receive the program's standard HCV counseling; vs an intervention cohort, which will view the education video. Subjects will undergo written testing for knowledge, attitudes about transmission behaviors, and motivations toward behavior change before the intervention, immediately after the intervention, 4 weeks after the intervention, and 12 weeks after the intervention. Additionally, we will measure and compare the rates of HCV testing and HAV/HBV vaccinations before and at the end of the 12 week time point in both cohorts.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 and older
  • Attendance at syringe exchange program

Exclusion criteria

  • Unable to provide informed consent
  • Not interested in study
  • Not able to speak or understand English

Treatment and study plan

Hepatitis C educational video

Procedure

Primary outcomes

  1. HCV testing rates, intervention vs. usual care

  2. HAV vaccination rates, intervention vs. usual care

  3. HBV vaccination rates, intervention vs. usual care

Secondary outcomes

  1. Improvement in knowledge, intervention vs. usual care

  2. Improvement in attitudes toward behavior change, intervention vs. usual care

  3. Improvement in motivations toward behavior change, intervention vs. usual care

Sponsors and collaborators

Lead sponsor

Organization to Achieve Solutions in Substance Abuse (OASIS)

Other

Collaborators

  • Centers for Disease Control and Prevention

Registry information

Official study title

Cooperative Agreement to Develop, Implement, and Evaluate Viral Hepatitis and Training

Important dates

Study start
2005
Primary completion
2007
Study completion
2007
First posted
Oct 19, 2005
Registry last updated
Dec 9, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.